Who are Antiplatelet Agents's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Plavix, Aspirin, Rosuvastatin plus clopidogrel, Ligustrazine by mouth, CYP2C19 genotype guided P2Y12 monotherapy, lysine acetylsalicylate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/antiplatelet-agents.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Antiplatelet Agents — Competitive Intelligence Brief

Antiplatelet Agents (Antiplatelet Agents) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiplatelet agent. Area: Cardiovascular.

marketed Antiplatelet agent Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Antiplatelet Agents (Antiplatelet Agents) — Beijing Tiantan Hospital. Antiplatelet agents inhibit platelet aggregation and clot formation by blocking platelet activation pathways.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Antiplatelet Agents TARGET	Antiplatelet Agents	Beijing Tiantan Hospital	marketed	Antiplatelet agent
Plavix	clopidogrel	Generic (originally Sanofi/BMS)	marketed	Thienopyridine antiplatelet agent	Cytochrome P450 2B6, P2Y purinoceptor 12, Sodium-dependent serotonin transporter	1997-11-17
Aspirin	acetylsalicylic acid	Bayer AG	marketed	NSAID, Antiplatelet agent	Gamma-glutamyltranspeptidase 1, Nicotinate phosphoribosyltransferase, Acid-sensing ion channel 3	1899-03-06
Rosuvastatin plus clopidogrel	Rosuvastatin plus clopidogrel	Federal University of São Paulo	marketed	Statin plus antiplatelet agent combination	HMG-CoA reductase; P2Y12 receptor
Ligustrazine by mouth	Ligustrazine by mouth	Shenzhen Kangning Hospital	marketed	Antiplatelet agent / Vasodilator
CYP2C19 genotype guided P2Y12 monotherapy	CYP2C19 genotype guided P2Y12 monotherapy	St. Antonius Hospital	marketed	P2Y12 inhibitor (antiplatelet agent)	P2Y12 receptor
lysine acetylsalicylate	lysine acetylsalicylate	Azienda Ospedaliera San Giovanni Battista	marketed	Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiplatelet agent class)

Asan Medical Center · 1 drug in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Beijing Tiantan Hospital · 1 drug in this class
Centre Hospitalier Universitaire de Saint Etienne · 1 drug in this class
China National Center for Cardiovascular Diseases · 1 drug in this class
Hospital Israelita Albert Einstein · 1 drug in this class
Icahn School of Medicine at Mount Sinai · 1 drug in this class
PLx Pharma · 1 drug in this class
Sichuan Provincial People's Hospital · 1 drug in this class
The George Institute for Global Health, China · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Antiplatelet Agents — Competitive Intelligence Brief. https://druglandscape.com/ci/antiplatelet-agents. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab